Compare Global Payments Inc (GPN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Recursion Pharmaceuticals Inc — how do they compare? Global Payments Inc trades at $79.21 (market cap $21.40B), while Recursion Pharmaceuticals Inc trades at $3.18 (market cap $1.75B). The key difference: Global Payments Inc is far larger — about 12.2× Recursion Pharmaceuticals Inc's market cap, and Global Payments Inc pays a 1.28% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GPN | RXRX | |
|---|---|---|
Market Cap | $21.40B | $1.75B |
Sector | Industrials | Health |
52-Week High | $90.01 | $6.79 |
52-Week Low | $62.47 | $2.84 |
Enterprise Value | $39.11B | $1.17B |
Dividend Yield | 1.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $75.89, down 1.25% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company maintains solid cash flow generation ($2.66B operating cash flow in 2025) and recently announced a $0.25 dividend. Despite negative net income margin and ROE, revenue trends show recovery potential with 2026 projections at $8.9B. Analyst consensus remains positive with 58% buy ratings and $81.56 price target.
GPN presents a mixed outlook with strong operational execution offset by profitability challenges. The Worldpay integration and AI-powered POS expansion offer growth catalysts, but margin pressure and rising debt levels pose risks. Current valuation at 28.76 P/E appears reasonable given the company's market position in payment technology, though investors should monitor competitive pressures in the fintech space.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
